Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/biology-technology-1/pharmasset-to-present-at-the-bio-ceo--26-investor-conference-2008-on-monday--february-11th-2931-2/) was not found.

Search biology technology 1 pharmasset to present at the bio ceo 26 investor conference 2008 on monday february 11th 2931 2 at Google

Search biology technology 1 pharmasset to present at the bio ceo 26 investor conference 2008 on monday february 11th 2931 2 at Yahoo

Search biology technology 1 pharmasset to present at the bio ceo 26 investor conference 2008 on monday february 11th 2931 2 at Msn

Google
 
(Date:11/24/2009)...NEW YORK (November 24, 2009) -- The Wildlife Conse...ealing that the last remaining population of Siber...o the rising tide of poaching and habitat loss. ,... Russian officials of what needs to be done to pro...cat. , The report was released by t...
(Date:11/24/2009)...s fish food is a matter of debate. A high-profile ...st 50 percent of their carbon from trees and leave...estrial and aquatic ecosystems. , But new resear... not likely to be true. Algae provide a much riche...to research published this week in the Proceeding...
(Date:11/24/2009)... available in Spanish . , The presence of i...inflammatory substances in the blood, hinders the ... research project of the University of Navarra con... the School of Pharmacy. , The project, entitled...n to the control of body weight and inflammation,"...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2VBI awarded 2427 million from NIH to support infectious disease research 10266 1VBI awarded 2427 million from NIH to support infectious disease research 10266 2VBI awarded 2427 million from NIH to support infectious disease research 10266 3VBI awarded 2427 million from NIH to support infectious disease research 10266 4Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 1Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 2Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 1 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 4 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 5 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 6
(Date:11/27/2009)..., Nov. 27 Preventing di...d fortunately every year, new vaccines are being a...accines boost immunity for the same period of time... needed to keep immunity strong? ,, In this m...rican Academy of Pediatrics, Michael Pichichero MD...
(Date:11/27/2009)...ecedented medical, economic burdens, study predict...- The number of people with diabetes in the United...rs, a new study predicts. , That would bring th...the disease, up from 23.7 million today. , , At ...abetes will triple, the study also warns, rising f...
(Date:11/27/2009)...hree new interactive anatomy education apps from M...nd health sciences learning opportunities for iPho...m, NC (Vocus) November 27, 2009 -- Modality, Inc....ivision of Wolters Kluwer Health, today announced ...ps on the App Store. Clemente’s Anatomy, Roh...
(Date:11/26/2009)...oo heavy can lead to strains or worse , ,...be nothing wrong with stuffing your turkey full to...hing with your suitcase as you pack for holiday tr...2008 in U.S. hospital emergency rooms, doctors, of...ggage-related injuries, such as muscle strains, pu...
(Date:11/26/2009)...enton Communications announces a highly effective ...ilers struggling to make an economic recovery. , ...-- Flu fears is the type of challenge that could s...cording to Dr. David Benton, business growth exper... system – The Rfactor Intensive . “...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Pharmacist Injects Cure for Ailing Businesses 2
Cyno Serum from Innovative Research
Marmoset serum from Alpha Genesis, Inc.
Anti-Foam Reagent from Promega
EPH electrode, cathode from GE Healthcare, formerly Amersham Biosciences
Biology Products:
Kratz-Barraquer Eye Speculum
Lehner Temporal Speculum
Wiener Eye Speculum
McKinney Eye Speculum
Medicine Products:
(Date:11/24/2009)...e-FirstCall/ -- IES (Nasdaq: IESC ), a leading na...ystems and services for the commercial, industrial... commercial business group has been awarded a cont...rical systems for the Level 4 bio-safety lab (BSL-...esearch Institute of Infectious Diseases (USAMRIID...
(Date:11/24/2009)...land, November 24 deCODE...at it has received notice from,the Nasdaq Stock Ma...ll be,suspended as of November 30, 2009 and a Form...ange Commission, which will remove deCODE,s common...files an appeal to the Nasdaq,Listing Qualificatio...
(Date:11/24/2009)... NeurogesX, Inc. (Nasdaq:...eveloping and commercializing novel pain managemen... President and Chief Executive Officer, is schedul...lth Care Conference, to be held December 1-2, 2009...k. ,, Mr. DiTonno and Stephen Ghiglieri, Chief...
(Date:11/24/2009)...O, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Thorn..., a leading provider of advanced laser systems and...ity clinic markets, today reported operational and...tember 30, 2009. , , Q3 2009 Highlights, -...illion in Q3 2008, - Gross profit margin was ...
Breaking Biology Technology:Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10
(Date:11/25/2009)...e/ -- Reportlinker.com announces that a new market..., Mammography Equipment - A Global Market Pers...330/Mammography-Equipment---A-Global-Market-Perspe...r in industrialized as well as developing nations ...mmography market. Globally, escalating awareness a...
(Date:11/25/2009)...Newswire/ -- Cempra Pharmaceuticals Inc. today ann...hief executive officer, will present at the Piper ... a.m. EST, December 1, 2009, at The New York Palac...ide an overview of the company,s two leading antib...resistant pathogens including MRSA. ,, About C...
(Date:11/25/2009)...ewswire/ -- ChemoCentryx, Inc., announced today ... PROTECT-1 (the Prospective Randomized Oral Therap...-EN(TM) (CCX282-B) in patients with moderate-to-se...y with a favorable safety and tolerability profile...icacy in the reduction of disease severity as defi...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 1FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 2FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 3FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 4FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 5FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 6FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 7FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 8PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 1PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 3Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 1Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 2Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 3